On September 3, 2019 Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement (C5) and/or leukotriene (LTB4) systems are implicated, reported that Clive Richardson, Chief Executive Officer, will participate and host investor meetings at the following September Conferences (Press release, Akari Therapeutics, SEP 3, 2019, https://www.akaritx.com/2019/09/03/akari-therapeutics-to-participate-in-citi-and-h-c-wainwright-conferences-in-early-september/ [SID1234539183]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 14th Annual Biotech Conference

Date: Wednesday, September 4, 2019

Place: Four Seasons, Boston, Mass.

H.C. Wainwright 21st Annual Global Investment Conference

Date: Tuesday, September 10, 2019

Place: Lotte New York Palace, New York City

Presentation Time: 12:30 p.m. ET

A live audio webcast of the H.C. Wainwright Conference presentation can be accessed by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com. An archived replay of the webcast will be available for 60 days on the Company’s website after the conference.
Investors interested in arranging a meeting with the Company’s management during these two conferences should contact the respective conference coordinators.